Review



ice cold flow cytometry staining buffer  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98

    Structured Review

    Thermo Fisher ice cold flow cytometry staining buffer
    HEL inhibits cell proliferation, induces apoptosis and differentiation in AML cells. (A) Structure of HEL highlighting (in red) three potentially thiol reactive sites. (B, C) Calculation of IC 50 for HEL using MTT dose response curves expressed as the log of concentration vs. cell viability of the AML or HMSC cells ( n = 5). (D) the effect of HEL (5 μmol/L) on cell apoptosis of multiple AML cells was analyzed by FCM with AraC (5 μmol/L) as the positive group ( n = 3). (E) AML cells were treated with DMSO, HEL (5 μmol/L) or ATRA (5 μmol/L) for 5 days as indicated. CD11b or CD14 expression was measured by FCM, the positive cell population percentage of CD11b or CD14 cells analysis results were presented ( n = 3). Representative flow <t>cytometry</t> charts of experiments D and E are shown in , CTR means control group. All data are presented as Median ± IQR, ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.001.
    Ice Cold Flow Cytometry Staining Buffer, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 469 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ice cold flow cytometry staining buffer/product/Thermo Fisher
    Average 98 stars, based on 469 article reviews
    ice cold flow cytometry staining buffer - by Bioz Stars, 2026-02
    98/100 stars

    Images

    1) Product Images from "Heliangin acts as a covalent ligand of RPS2 that disrupts pre-rRNA metabolic processes in NPM1 -mutated acute myeloid leukemia"

    Article Title: Heliangin acts as a covalent ligand of RPS2 that disrupts pre-rRNA metabolic processes in NPM1 -mutated acute myeloid leukemia

    Journal: Acta Pharmaceutica Sinica. B

    doi: 10.1016/j.apsb.2022.10.018

    HEL inhibits cell proliferation, induces apoptosis and differentiation in AML cells. (A) Structure of HEL highlighting (in red) three potentially thiol reactive sites. (B, C) Calculation of IC 50 for HEL using MTT dose response curves expressed as the log of concentration vs. cell viability of the AML or HMSC cells ( n = 5). (D) the effect of HEL (5 μmol/L) on cell apoptosis of multiple AML cells was analyzed by FCM with AraC (5 μmol/L) as the positive group ( n = 3). (E) AML cells were treated with DMSO, HEL (5 μmol/L) or ATRA (5 μmol/L) for 5 days as indicated. CD11b or CD14 expression was measured by FCM, the positive cell population percentage of CD11b or CD14 cells analysis results were presented ( n = 3). Representative flow cytometry charts of experiments D and E are shown in , CTR means control group. All data are presented as Median ± IQR, ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.001.
    Figure Legend Snippet: HEL inhibits cell proliferation, induces apoptosis and differentiation in AML cells. (A) Structure of HEL highlighting (in red) three potentially thiol reactive sites. (B, C) Calculation of IC 50 for HEL using MTT dose response curves expressed as the log of concentration vs. cell viability of the AML or HMSC cells ( n = 5). (D) the effect of HEL (5 μmol/L) on cell apoptosis of multiple AML cells was analyzed by FCM with AraC (5 μmol/L) as the positive group ( n = 3). (E) AML cells were treated with DMSO, HEL (5 μmol/L) or ATRA (5 μmol/L) for 5 days as indicated. CD11b or CD14 expression was measured by FCM, the positive cell population percentage of CD11b or CD14 cells analysis results were presented ( n = 3). Representative flow cytometry charts of experiments D and E are shown in , CTR means control group. All data are presented as Median ± IQR, ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.001.

    Techniques Used: Concentration Assay, Expressing, Flow Cytometry, Control

    The in vivo effect of HEL on NPM1 mutant AML cells. (A) Experiment schema. After confirmation of bone marrow AML engraftment to >10% in 3 randomly selected mice, remaining mice were randomized to model, 50 mg/kg HEL, or 50 mg/kg AraC, by i. p. every 48 h for 14 days (B) Bone marrow AML burden. Representative flow cytometry for Human CD45 + (AML) and mouse CD45 + (normal) cells. (C) Granulocyte (CD11b) and monocyte (CD14) lineage differentiation marker expression in marrow AML cells using FCM analysis. (D, E) Photos show spleens from model M-NSG mice and different treatment groups, with H&E-stained spleen sections showing splenic lesions (yellow arrow). Scale bar, 12 μm. (F) Serial blood counts. The increasing of WBC and decreasing of Hb or PLT was due to myeloblasts. All the above experiments were analyzed by ten mice per group (vehicle group, n = 5), presented as Median ± IQR, ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.
    Figure Legend Snippet: The in vivo effect of HEL on NPM1 mutant AML cells. (A) Experiment schema. After confirmation of bone marrow AML engraftment to >10% in 3 randomly selected mice, remaining mice were randomized to model, 50 mg/kg HEL, or 50 mg/kg AraC, by i. p. every 48 h for 14 days (B) Bone marrow AML burden. Representative flow cytometry for Human CD45 + (AML) and mouse CD45 + (normal) cells. (C) Granulocyte (CD11b) and monocyte (CD14) lineage differentiation marker expression in marrow AML cells using FCM analysis. (D, E) Photos show spleens from model M-NSG mice and different treatment groups, with H&E-stained spleen sections showing splenic lesions (yellow arrow). Scale bar, 12 μm. (F) Serial blood counts. The increasing of WBC and decreasing of Hb or PLT was due to myeloblasts. All the above experiments were analyzed by ten mice per group (vehicle group, n = 5), presented as Median ± IQR, ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.

    Techniques Used: In Vivo, Mutagenesis, Flow Cytometry, Marker, Expressing, Staining

    HEL impairs NPM1 mutant AML cells and induces cell differentiation through targeting RPS2. (A) Anti-FLAG, anti-RPS2 and loading control anti- β -actin protein expression in OCI-AML3 cells stably expressing FLAG-GFP, FLAG-RPS2 WT or FLAG-RPS2 C222S mutant assessed using western blotting. (B)–(E) Cell viability (B, n = 6); cycles (C, n = 5), apoptotic rates (D, n = 3) and differentiation status (E, n = 3) of OCI-AML3 cells transiently expressing pcDNA3.1 vector, FLAG-RPS2 WT or a FLAG-RPS2 C222S mutant treated with DMSO or HEL (5 μmol/L) for 48 h, cell viability was tested by MTT method and cell cycle, apoptosis, and differentiation were all tested by flow cytometry method. Representative flow cytometry charts of experiments C&D are shown in . All the above experiments were analyzed by at least three biological replicates, presented as Median ± IQR; ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.
    Figure Legend Snippet: HEL impairs NPM1 mutant AML cells and induces cell differentiation through targeting RPS2. (A) Anti-FLAG, anti-RPS2 and loading control anti- β -actin protein expression in OCI-AML3 cells stably expressing FLAG-GFP, FLAG-RPS2 WT or FLAG-RPS2 C222S mutant assessed using western blotting. (B)–(E) Cell viability (B, n = 6); cycles (C, n = 5), apoptotic rates (D, n = 3) and differentiation status (E, n = 3) of OCI-AML3 cells transiently expressing pcDNA3.1 vector, FLAG-RPS2 WT or a FLAG-RPS2 C222S mutant treated with DMSO or HEL (5 μmol/L) for 48 h, cell viability was tested by MTT method and cell cycle, apoptosis, and differentiation were all tested by flow cytometry method. Representative flow cytometry charts of experiments C&D are shown in . All the above experiments were analyzed by at least three biological replicates, presented as Median ± IQR; ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.

    Techniques Used: Mutagenesis, Cell Differentiation, Control, Expressing, Stable Transfection, Western Blot, Plasmid Preparation, Flow Cytometry

    RPS2 is an essential target for NPM1 mutant AML treatment, and this target is p53 dependent. OCI-AML3 sh NC (blue) or sh p53 (red) cells transfected with RPS2 siRNA or si NC (control) and treated with DMSO or HEL (5 μmol/L), respectively for 48 h, the cells were then tested for the (A) proliferation, (B) apoptosis, (C) cycle arrest, and (D) differentiation status [a, DMSO; b, si NC ; c, HEL (5 μmol/L)+si NC ; d, si RPS2 ; e, HEL (5 μmol/L)+si RPS2 ] and (E) expressions of p53, RPS2, caspase 3, C-caspase 3, p21 and CEBP/ α proteins. Experiments (A ) was analyzed by five biological replicates; experiments (B–D ) were analyzed by three biological replicates. Representative flow cytometry charts of experiments B&C are shown in . All data are presented as Median ± IQR; ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, unpaired t test; gels shown in experiment (E) are representative blots for three biological independent samples per group; Protein level quantification results are shown in <xref ref-type=Supporting Information Fig. S15. (F) Expression of RPS2 protein and loading control actin levels in OCI-AML3 cells transfected with RPS2 siRNA and siNC (control), assessed using Western blot. (G, H) Northern blot analysis of pre-rRNA processing phenotypes after transfected with RPS2 siRNA or si NC (control) treated with DMSO or HEL (10 μmol/L) for 48 h, respectively. Mature rRNAs were shown on the EtBr-stained gel. Bands on the Northern blots or EtBr gels ( n = 3) were quantitated by ImageJ, presented as Median ± IQR; ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001. (I) FBL (red) and NPM1 (green) localization in the RPS2 knock-down OCI-AML3 cells by IF. Hoechst 33342 (blue) was used to stain for nuclei. Images by Leica SP8 confocal microscope. Scale bar, 12.3 μm. Quantification of percentage of cells with nucleolar stress is shown in Supporting Information Fig. S16 . " title="... were analyzed by three biological replicates. Representative flow cytometry charts of experiments B&C are shown in . ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: RPS2 is an essential target for NPM1 mutant AML treatment, and this target is p53 dependent. OCI-AML3 sh NC (blue) or sh p53 (red) cells transfected with RPS2 siRNA or si NC (control) and treated with DMSO or HEL (5 μmol/L), respectively for 48 h, the cells were then tested for the (A) proliferation, (B) apoptosis, (C) cycle arrest, and (D) differentiation status [a, DMSO; b, si NC ; c, HEL (5 μmol/L)+si NC ; d, si RPS2 ; e, HEL (5 μmol/L)+si RPS2 ] and (E) expressions of p53, RPS2, caspase 3, C-caspase 3, p21 and CEBP/ α proteins. Experiments (A ) was analyzed by five biological replicates; experiments (B–D ) were analyzed by three biological replicates. Representative flow cytometry charts of experiments B&C are shown in . All data are presented as Median ± IQR; ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, unpaired t test; gels shown in experiment (E) are representative blots for three biological independent samples per group; Protein level quantification results are shown in Supporting Information Fig. S15. (F) Expression of RPS2 protein and loading control actin levels in OCI-AML3 cells transfected with RPS2 siRNA and siNC (control), assessed using Western blot. (G, H) Northern blot analysis of pre-rRNA processing phenotypes after transfected with RPS2 siRNA or si NC (control) treated with DMSO or HEL (10 μmol/L) for 48 h, respectively. Mature rRNAs were shown on the EtBr-stained gel. Bands on the Northern blots or EtBr gels ( n = 3) were quantitated by ImageJ, presented as Median ± IQR; ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001. (I) FBL (red) and NPM1 (green) localization in the RPS2 knock-down OCI-AML3 cells by IF. Hoechst 33342 (blue) was used to stain for nuclei. Images by Leica SP8 confocal microscope. Scale bar, 12.3 μm. Quantification of percentage of cells with nucleolar stress is shown in Supporting Information Fig. S16 .

    Techniques Used: Mutagenesis, Transfection, Control, Flow Cytometry, Expressing, Western Blot, Northern Blot, Staining, Knockdown, Microscopy



    Similar Products

    99
    R&D Systems ice cold flow cytometry staining buffer 1x
    Ice Cold Flow Cytometry Staining Buffer 1x, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ice cold flow cytometry staining buffer 1x/product/R&D Systems
    Average 99 stars, based on 1 article reviews
    ice cold flow cytometry staining buffer 1x - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    98
    Thermo Fisher ice cold flow cytometry staining buffer
    HEL inhibits cell proliferation, induces apoptosis and differentiation in AML cells. (A) Structure of HEL highlighting (in red) three potentially thiol reactive sites. (B, C) Calculation of IC 50 for HEL using MTT dose response curves expressed as the log of concentration vs. cell viability of the AML or HMSC cells ( n = 5). (D) the effect of HEL (5 μmol/L) on cell apoptosis of multiple AML cells was analyzed by FCM with AraC (5 μmol/L) as the positive group ( n = 3). (E) AML cells were treated with DMSO, HEL (5 μmol/L) or ATRA (5 μmol/L) for 5 days as indicated. CD11b or CD14 expression was measured by FCM, the positive cell population percentage of CD11b or CD14 cells analysis results were presented ( n = 3). Representative flow <t>cytometry</t> charts of experiments D and E are shown in , CTR means control group. All data are presented as Median ± IQR, ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.001.
    Ice Cold Flow Cytometry Staining Buffer, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ice cold flow cytometry staining buffer/product/Thermo Fisher
    Average 98 stars, based on 1 article reviews
    ice cold flow cytometry staining buffer - by Bioz Stars, 2026-02
    98/100 stars
      Buy from Supplier

    94
    R&D Systems ice cold flow cytometry staining buffer
    HEL inhibits cell proliferation, induces apoptosis and differentiation in AML cells. (A) Structure of HEL highlighting (in red) three potentially thiol reactive sites. (B, C) Calculation of IC 50 for HEL using MTT dose response curves expressed as the log of concentration vs. cell viability of the AML or HMSC cells ( n = 5). (D) the effect of HEL (5 μmol/L) on cell apoptosis of multiple AML cells was analyzed by FCM with AraC (5 μmol/L) as the positive group ( n = 3). (E) AML cells were treated with DMSO, HEL (5 μmol/L) or ATRA (5 μmol/L) for 5 days as indicated. CD11b or CD14 expression was measured by FCM, the positive cell population percentage of CD11b or CD14 cells analysis results were presented ( n = 3). Representative flow <t>cytometry</t> charts of experiments D and E are shown in , CTR means control group. All data are presented as Median ± IQR, ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.001.
    Ice Cold Flow Cytometry Staining Buffer, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ice cold flow cytometry staining buffer/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    ice cold flow cytometry staining buffer - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    90
    Thermo Fisher 400 ul ice-cold flow cytometry staining buffer
    A, Schema for splenocyte adoptive transfer experiments. Splenocytes were isolated from CD45.2 sham and HF mice 8 weeks after coronary ligation or sham operation and transferred to syngeneic CD45.1 mice. Recipient mice were then followed for an 8-week period. B, M-mode ECGs from recipient mice 8 weeks after receiving splenocytes from sham or HF mice. C, Serial group echocardiographic data for end-diastolic volume (EDV), end-systolic volume (ESV), and ejection fraction (EF) during the 8-week follow-up period after cell transfer (n=7 per group). D, Similar echocardiographic data in parallel groups of mice after adoptive transfer of splenocytes derived from donors treated with either lipopolysaccharide (LPS) or PBS control (n=7 per group). E, Representative hearts from mice receiving HF or sham splenocytes and corresponding heart and lung gravimetric group data. F, Flow <t>cytometry</t> scatter plots and quantification of circulating CD11b+F4/80+ monocytes in recipient mice 8 weeks after cell transfer. G, Examples of spleens harvested from mice receiving HF or sham splenocytes, corresponding spleen gravimetry, and representative trichrome-stained histological sections from the same. N=4 to 6 per group (E–G).
    400 Ul Ice Cold Flow Cytometry Staining Buffer, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/400 ul ice-cold flow cytometry staining buffer/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    400 ul ice-cold flow cytometry staining buffer - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher ice-cold flow cytometry staining buffer
    a Flow <t>cytometry</t> gating strategy used to identify circulating CD45+CD11b+F4/80lowLy6Chi and CD45+CD11b+F4/80lowLy6Clow monocytes using the lymphocyte–monocyte gate from initial side vs. forward scatter plots (SSC vs. FSC, respectively). b Quantitative group data for total blood CD11b+F4/80+ cells, and Ly6Chi and Ly6low subsets, in WTc and iNOS−/−c sham and HF mice. *p < 0.05, **p < 0.005, ***p < 0.0005 (two-way ANOVA with Bonferroni post-test); n = 4–6/group
    Ice Cold Flow Cytometry Staining Buffer, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ice-cold flow cytometry staining buffer/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    ice-cold flow cytometry staining buffer - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    HEL inhibits cell proliferation, induces apoptosis and differentiation in AML cells. (A) Structure of HEL highlighting (in red) three potentially thiol reactive sites. (B, C) Calculation of IC 50 for HEL using MTT dose response curves expressed as the log of concentration vs. cell viability of the AML or HMSC cells ( n = 5). (D) the effect of HEL (5 μmol/L) on cell apoptosis of multiple AML cells was analyzed by FCM with AraC (5 μmol/L) as the positive group ( n = 3). (E) AML cells were treated with DMSO, HEL (5 μmol/L) or ATRA (5 μmol/L) for 5 days as indicated. CD11b or CD14 expression was measured by FCM, the positive cell population percentage of CD11b or CD14 cells analysis results were presented ( n = 3). Representative flow cytometry charts of experiments D and E are shown in , CTR means control group. All data are presented as Median ± IQR, ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.001.

    Journal: Acta Pharmaceutica Sinica. B

    Article Title: Heliangin acts as a covalent ligand of RPS2 that disrupts pre-rRNA metabolic processes in NPM1 -mutated acute myeloid leukemia

    doi: 10.1016/j.apsb.2022.10.018

    Figure Lengend Snippet: HEL inhibits cell proliferation, induces apoptosis and differentiation in AML cells. (A) Structure of HEL highlighting (in red) three potentially thiol reactive sites. (B, C) Calculation of IC 50 for HEL using MTT dose response curves expressed as the log of concentration vs. cell viability of the AML or HMSC cells ( n = 5). (D) the effect of HEL (5 μmol/L) on cell apoptosis of multiple AML cells was analyzed by FCM with AraC (5 μmol/L) as the positive group ( n = 3). (E) AML cells were treated with DMSO, HEL (5 μmol/L) or ATRA (5 μmol/L) for 5 days as indicated. CD11b or CD14 expression was measured by FCM, the positive cell population percentage of CD11b or CD14 cells analysis results were presented ( n = 3). Representative flow cytometry charts of experiments D and E are shown in , CTR means control group. All data are presented as Median ± IQR, ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.001.

    Article Snippet: For the FCM differentiation assay, cells were washed with ice-cold flow cytometry staining buffer (FCS, #00-4222-26, eBioscience) twice, resuspended in 100 μL FCS buffer, and then stained with FITC-anti-human CD11b or APC-anti-human CD14 for 45 min on ice.

    Techniques: Concentration Assay, Expressing, Flow Cytometry, Control

    The in vivo effect of HEL on NPM1 mutant AML cells. (A) Experiment schema. After confirmation of bone marrow AML engraftment to >10% in 3 randomly selected mice, remaining mice were randomized to model, 50 mg/kg HEL, or 50 mg/kg AraC, by i. p. every 48 h for 14 days (B) Bone marrow AML burden. Representative flow cytometry for Human CD45 + (AML) and mouse CD45 + (normal) cells. (C) Granulocyte (CD11b) and monocyte (CD14) lineage differentiation marker expression in marrow AML cells using FCM analysis. (D, E) Photos show spleens from model M-NSG mice and different treatment groups, with H&E-stained spleen sections showing splenic lesions (yellow arrow). Scale bar, 12 μm. (F) Serial blood counts. The increasing of WBC and decreasing of Hb or PLT was due to myeloblasts. All the above experiments were analyzed by ten mice per group (vehicle group, n = 5), presented as Median ± IQR, ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.

    Journal: Acta Pharmaceutica Sinica. B

    Article Title: Heliangin acts as a covalent ligand of RPS2 that disrupts pre-rRNA metabolic processes in NPM1 -mutated acute myeloid leukemia

    doi: 10.1016/j.apsb.2022.10.018

    Figure Lengend Snippet: The in vivo effect of HEL on NPM1 mutant AML cells. (A) Experiment schema. After confirmation of bone marrow AML engraftment to >10% in 3 randomly selected mice, remaining mice were randomized to model, 50 mg/kg HEL, or 50 mg/kg AraC, by i. p. every 48 h for 14 days (B) Bone marrow AML burden. Representative flow cytometry for Human CD45 + (AML) and mouse CD45 + (normal) cells. (C) Granulocyte (CD11b) and monocyte (CD14) lineage differentiation marker expression in marrow AML cells using FCM analysis. (D, E) Photos show spleens from model M-NSG mice and different treatment groups, with H&E-stained spleen sections showing splenic lesions (yellow arrow). Scale bar, 12 μm. (F) Serial blood counts. The increasing of WBC and decreasing of Hb or PLT was due to myeloblasts. All the above experiments were analyzed by ten mice per group (vehicle group, n = 5), presented as Median ± IQR, ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.

    Article Snippet: For the FCM differentiation assay, cells were washed with ice-cold flow cytometry staining buffer (FCS, #00-4222-26, eBioscience) twice, resuspended in 100 μL FCS buffer, and then stained with FITC-anti-human CD11b or APC-anti-human CD14 for 45 min on ice.

    Techniques: In Vivo, Mutagenesis, Flow Cytometry, Marker, Expressing, Staining

    HEL impairs NPM1 mutant AML cells and induces cell differentiation through targeting RPS2. (A) Anti-FLAG, anti-RPS2 and loading control anti- β -actin protein expression in OCI-AML3 cells stably expressing FLAG-GFP, FLAG-RPS2 WT or FLAG-RPS2 C222S mutant assessed using western blotting. (B)–(E) Cell viability (B, n = 6); cycles (C, n = 5), apoptotic rates (D, n = 3) and differentiation status (E, n = 3) of OCI-AML3 cells transiently expressing pcDNA3.1 vector, FLAG-RPS2 WT or a FLAG-RPS2 C222S mutant treated with DMSO or HEL (5 μmol/L) for 48 h, cell viability was tested by MTT method and cell cycle, apoptosis, and differentiation were all tested by flow cytometry method. Representative flow cytometry charts of experiments C&D are shown in . All the above experiments were analyzed by at least three biological replicates, presented as Median ± IQR; ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.

    Journal: Acta Pharmaceutica Sinica. B

    Article Title: Heliangin acts as a covalent ligand of RPS2 that disrupts pre-rRNA metabolic processes in NPM1 -mutated acute myeloid leukemia

    doi: 10.1016/j.apsb.2022.10.018

    Figure Lengend Snippet: HEL impairs NPM1 mutant AML cells and induces cell differentiation through targeting RPS2. (A) Anti-FLAG, anti-RPS2 and loading control anti- β -actin protein expression in OCI-AML3 cells stably expressing FLAG-GFP, FLAG-RPS2 WT or FLAG-RPS2 C222S mutant assessed using western blotting. (B)–(E) Cell viability (B, n = 6); cycles (C, n = 5), apoptotic rates (D, n = 3) and differentiation status (E, n = 3) of OCI-AML3 cells transiently expressing pcDNA3.1 vector, FLAG-RPS2 WT or a FLAG-RPS2 C222S mutant treated with DMSO or HEL (5 μmol/L) for 48 h, cell viability was tested by MTT method and cell cycle, apoptosis, and differentiation were all tested by flow cytometry method. Representative flow cytometry charts of experiments C&D are shown in . All the above experiments were analyzed by at least three biological replicates, presented as Median ± IQR; ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001.

    Article Snippet: For the FCM differentiation assay, cells were washed with ice-cold flow cytometry staining buffer (FCS, #00-4222-26, eBioscience) twice, resuspended in 100 μL FCS buffer, and then stained with FITC-anti-human CD11b or APC-anti-human CD14 for 45 min on ice.

    Techniques: Mutagenesis, Cell Differentiation, Control, Expressing, Stable Transfection, Western Blot, Plasmid Preparation, Flow Cytometry

    RPS2 is an essential target for NPM1 mutant AML treatment, and this target is p53 dependent. OCI-AML3 sh NC (blue) or sh p53 (red) cells transfected with RPS2 siRNA or si NC (control) and treated with DMSO or HEL (5 μmol/L), respectively for 48 h, the cells were then tested for the (A) proliferation, (B) apoptosis, (C) cycle arrest, and (D) differentiation status [a, DMSO; b, si NC ; c, HEL (5 μmol/L)+si NC ; d, si RPS2 ; e, HEL (5 μmol/L)+si RPS2 ] and (E) expressions of p53, RPS2, caspase 3, C-caspase 3, p21 and CEBP/ α proteins. Experiments (A ) was analyzed by five biological replicates; experiments (B–D ) were analyzed by three biological replicates. Representative flow cytometry charts of experiments B&C are shown in . All data are presented as Median ± IQR; ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, unpaired t test; gels shown in experiment (E) are representative blots for three biological independent samples per group; Protein level quantification results are shown in <xref ref-type=Supporting Information Fig. S15. (F) Expression of RPS2 protein and loading control actin levels in OCI-AML3 cells transfected with RPS2 siRNA and siNC (control), assessed using Western blot. (G, H) Northern blot analysis of pre-rRNA processing phenotypes after transfected with RPS2 siRNA or si NC (control) treated with DMSO or HEL (10 μmol/L) for 48 h, respectively. Mature rRNAs were shown on the EtBr-stained gel. Bands on the Northern blots or EtBr gels ( n = 3) were quantitated by ImageJ, presented as Median ± IQR; ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001. (I) FBL (red) and NPM1 (green) localization in the RPS2 knock-down OCI-AML3 cells by IF. Hoechst 33342 (blue) was used to stain for nuclei. Images by Leica SP8 confocal microscope. Scale bar, 12.3 μm. Quantification of percentage of cells with nucleolar stress is shown in Supporting Information Fig. S16 . " width="100%" height="100%">

    Journal: Acta Pharmaceutica Sinica. B

    Article Title: Heliangin acts as a covalent ligand of RPS2 that disrupts pre-rRNA metabolic processes in NPM1 -mutated acute myeloid leukemia

    doi: 10.1016/j.apsb.2022.10.018

    Figure Lengend Snippet: RPS2 is an essential target for NPM1 mutant AML treatment, and this target is p53 dependent. OCI-AML3 sh NC (blue) or sh p53 (red) cells transfected with RPS2 siRNA or si NC (control) and treated with DMSO or HEL (5 μmol/L), respectively for 48 h, the cells were then tested for the (A) proliferation, (B) apoptosis, (C) cycle arrest, and (D) differentiation status [a, DMSO; b, si NC ; c, HEL (5 μmol/L)+si NC ; d, si RPS2 ; e, HEL (5 μmol/L)+si RPS2 ] and (E) expressions of p53, RPS2, caspase 3, C-caspase 3, p21 and CEBP/ α proteins. Experiments (A ) was analyzed by five biological replicates; experiments (B–D ) were analyzed by three biological replicates. Representative flow cytometry charts of experiments B&C are shown in . All data are presented as Median ± IQR; ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, unpaired t test; gels shown in experiment (E) are representative blots for three biological independent samples per group; Protein level quantification results are shown in Supporting Information Fig. S15. (F) Expression of RPS2 protein and loading control actin levels in OCI-AML3 cells transfected with RPS2 siRNA and siNC (control), assessed using Western blot. (G, H) Northern blot analysis of pre-rRNA processing phenotypes after transfected with RPS2 siRNA or si NC (control) treated with DMSO or HEL (10 μmol/L) for 48 h, respectively. Mature rRNAs were shown on the EtBr-stained gel. Bands on the Northern blots or EtBr gels ( n = 3) were quantitated by ImageJ, presented as Median ± IQR; ns, not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001. (I) FBL (red) and NPM1 (green) localization in the RPS2 knock-down OCI-AML3 cells by IF. Hoechst 33342 (blue) was used to stain for nuclei. Images by Leica SP8 confocal microscope. Scale bar, 12.3 μm. Quantification of percentage of cells with nucleolar stress is shown in Supporting Information Fig. S16 .

    Article Snippet: For the FCM differentiation assay, cells were washed with ice-cold flow cytometry staining buffer (FCS, #00-4222-26, eBioscience) twice, resuspended in 100 μL FCS buffer, and then stained with FITC-anti-human CD11b or APC-anti-human CD14 for 45 min on ice.

    Techniques: Mutagenesis, Transfection, Control, Flow Cytometry, Expressing, Western Blot, Northern Blot, Staining, Knockdown, Microscopy

    A, Schema for splenocyte adoptive transfer experiments. Splenocytes were isolated from CD45.2 sham and HF mice 8 weeks after coronary ligation or sham operation and transferred to syngeneic CD45.1 mice. Recipient mice were then followed for an 8-week period. B, M-mode ECGs from recipient mice 8 weeks after receiving splenocytes from sham or HF mice. C, Serial group echocardiographic data for end-diastolic volume (EDV), end-systolic volume (ESV), and ejection fraction (EF) during the 8-week follow-up period after cell transfer (n=7 per group). D, Similar echocardiographic data in parallel groups of mice after adoptive transfer of splenocytes derived from donors treated with either lipopolysaccharide (LPS) or PBS control (n=7 per group). E, Representative hearts from mice receiving HF or sham splenocytes and corresponding heart and lung gravimetric group data. F, Flow cytometry scatter plots and quantification of circulating CD11b+F4/80+ monocytes in recipient mice 8 weeks after cell transfer. G, Examples of spleens harvested from mice receiving HF or sham splenocytes, corresponding spleen gravimetry, and representative trichrome-stained histological sections from the same. N=4 to 6 per group (E–G).

    Journal: Circulation research

    Article Title: Remodeling of the Mononuclear Phagocyte Network Underlies Chronic Inflammation and Disease Progression in Heart Failure

    doi: 10.1161/CIRCRESAHA.113.301720

    Figure Lengend Snippet: A, Schema for splenocyte adoptive transfer experiments. Splenocytes were isolated from CD45.2 sham and HF mice 8 weeks after coronary ligation or sham operation and transferred to syngeneic CD45.1 mice. Recipient mice were then followed for an 8-week period. B, M-mode ECGs from recipient mice 8 weeks after receiving splenocytes from sham or HF mice. C, Serial group echocardiographic data for end-diastolic volume (EDV), end-systolic volume (ESV), and ejection fraction (EF) during the 8-week follow-up period after cell transfer (n=7 per group). D, Similar echocardiographic data in parallel groups of mice after adoptive transfer of splenocytes derived from donors treated with either lipopolysaccharide (LPS) or PBS control (n=7 per group). E, Representative hearts from mice receiving HF or sham splenocytes and corresponding heart and lung gravimetric group data. F, Flow cytometry scatter plots and quantification of circulating CD11b+F4/80+ monocytes in recipient mice 8 weeks after cell transfer. G, Examples of spleens harvested from mice receiving HF or sham splenocytes, corresponding spleen gravimetry, and representative trichrome-stained histological sections from the same. N=4 to 6 per group (E–G).

    Article Snippet: Leukocytes were collected by centrifugation (380 g for 10 minutes at 4°C) and resuspended in 400 uL ice-cold flow cytometry staining buffer (eBiosciences).

    Techniques: Adoptive Transfer Assay, Isolation, Ligation, Derivative Assay, Flow Cytometry, Staining

    a Flow cytometry gating strategy used to identify circulating CD45+CD11b+F4/80lowLy6Chi and CD45+CD11b+F4/80lowLy6Clow monocytes using the lymphocyte–monocyte gate from initial side vs. forward scatter plots (SSC vs. FSC, respectively). b Quantitative group data for total blood CD11b+F4/80+ cells, and Ly6Chi and Ly6low subsets, in WTc and iNOS−/−c sham and HF mice. *p < 0.05, **p < 0.005, ***p < 0.0005 (two-way ANOVA with Bonferroni post-test); n = 4–6/group

    Journal: Basic research in cardiology

    Article Title: Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure

    doi: 10.1007/s00395-017-0609-2

    Figure Lengend Snippet: a Flow cytometry gating strategy used to identify circulating CD45+CD11b+F4/80lowLy6Chi and CD45+CD11b+F4/80lowLy6Clow monocytes using the lymphocyte–monocyte gate from initial side vs. forward scatter plots (SSC vs. FSC, respectively). b Quantitative group data for total blood CD11b+F4/80+ cells, and Ly6Chi and Ly6low subsets, in WTc and iNOS−/−c sham and HF mice. *p < 0.05, **p < 0.005, ***p < 0.0005 (two-way ANOVA with Bonferroni post-test); n = 4–6/group

    Article Snippet: Leukocytes were collected by centrifugation (380g for 10 min at 4 °C) and resuspended in ice-cold flow cytometry staining buffer (eBioscience).

    Techniques: Flow Cytometry